Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49. https://doi.org/10.3322/caac.21820.

PubMed  Google Scholar 

Lowrance W, Dreicer R, Jarrard DF, et al. Updates to advanced prostate cancer: AUA/SUO guideline (2023). J Urol. 2023;209(6):1082–90. https://doi.org/10.1097/JU.0000000000003452.

PubMed  Google Scholar 

Moul JW. The evolving definition of advanced prostate cancer. Rev Urol. 2004;6(Suppl 8):S10–7.

PubMed  PubMed Central  Google Scholar 

Militaru FC, Militaru V, Crisan N, et al. Molecular basis and therapeutic targets in prostate cancer: a comprehensive review. Biomol Biomed. 2023;23(5):760–71. https://doi.org/10.17305/bb.2023.8782.

CAS  PubMed  Google Scholar 

Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6(2):76–85. https://doi.org/10.1038/ncpuro1296.

CAS  PubMed  PubMed Central  Google Scholar 

Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119–34. https://doi.org/10.1016/j.annonc.2020.06.011.

CAS  PubMed  Google Scholar 

Raja T, Sud R, Addla S, et al. Gonadotropin-releasing hormone agonists in prostate cancer: a comparative review of efficacy and safety. Indian J Cancer. 2022;59(Suppl 1):S142–59. https://doi.org/10.4103/ijc.IJC_65_21.

CAS  PubMed  Google Scholar 

Van Poppel H, Abrahamsson P-A. Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer. Int J Urol. 2020;27(10):830–7. https://doi.org/10.1111/iju.14303.

CAS  PubMed  Google Scholar 

U.S. Food & Drug Administration. Prescribing information: ORGOVYX (relugolix) tablets, for oral use. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf. Accessed May 16, 2024.

Crawford ED, Heidenreich A, Lawrentschuk N, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2019;22(1):24–38. https://doi.org/10.1038/s41391-018-0079-0.

PubMed  Google Scholar 

Dearnaley DP, Saltzstein DR, Sylvester JE, et al. The oral gonadotropin-releasing hormone receptor antagonist relugolix as neoadjuvant/adjuvant androgen deprivation therapy to external beam radiotherapy in patients with localised intermediate-risk prostate cancer: a randomised, open-label, parallel-group phase 2 trial. Eur Urol. 2020;78(2):184–92. https://doi.org/10.1016/j.eururo.2020.03.001.

CAS  PubMed  Google Scholar 

Henry MA, Leung A, Filson CP. Cost considerations for systemic therapy for patients with advanced genitourinary malignancies. Cancer. 2018;124(14):2897–905. https://doi.org/10.1002/cncr.31355.

PubMed  Google Scholar 

Borrelli E, McGladrigan CG. PCN80 estimating the difference in annual out-of-pocket costs for relugolix and leuprolide for medicare patients with metastatic prostate cancer. Value Health. 2021;24(Suppl 1):S34. https://doi.org/10.1016/j.jval.2021.04.172.

Google Scholar 

Thompson IM. Flare associated with LHRH-agonist therapy. Rev Urol. 2001;3(Suppl 3):S10–4.

PubMed  PubMed Central  Google Scholar 

Kaku H, Saika T, Tsushima T, et al. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Prostate. 2006;66(4):439–44. https://doi.org/10.1002/pros.20341.

CAS  PubMed  Google Scholar 

Nascimento B, Miranda EP, Jenkins LC, Benfante N, Schofield EA, Mulhall JP. Testosterone recovery profiles after cessation of androgen deprivation therapy for prostate cancer. J Sex Med. 2019;16(6):872–9. https://doi.org/10.1016/j.jsxm.2019.03.273.

PubMed  PubMed Central  Google Scholar 

Fradin J, Kim FJ, Lu-Yao GL, Storozynsky E, Kelly WK. Review of cardiovascular risk of androgen deprivation therapy and the influence of race in men with prostate cancer. Cancers (Basel). 2023;15(8):2316. https://doi.org/10.3390/cancers15082316.

CAS  PubMed  Google Scholar 

Klimis H, Pinthus JH, Aghel N, et al. The burden of uncontrolled cardiovascular risk factors in men with prostate cancer. JACC: CardioOncol. 2023;5(1):70–81. https://doi.org/10.1016/j.jaccao.2022.09.008.

PubMed  Google Scholar 

Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–56. https://doi.org/10.1200/JCO.2006.06.2497.

CAS  PubMed  Google Scholar 

O’Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015;33(11):1243–51. https://doi.org/10.1200/JCO.2014.59.1792.

CAS  PubMed  Google Scholar 

Shore ND, Abrahamsson P-A, Anderson J, Crawford ED, Lange P. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer Prostatic Dis. 2013;16(1):7–15. https://doi.org/10.1038/pcan.2012.25.

CAS  PubMed  Google Scholar 

Margel D, Peer A, Ber Y, et al. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease. J Urol. 2019;202(6):1199–208. https://doi.org/10.1097/JU.0000000000000384.

PubMed  Google Scholar 

Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65(3):565–73. https://doi.org/10.1016/j.eururo.2013.10.032.

CAS  PubMed  Google Scholar 

Shore ND, Saad F, Cookson MS, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382(23):2187–96. https://doi.org/10.1056/NEJMoa2004325.

CAS  PubMed  Google Scholar 

Lopes RD, Higano CS, Slovin SF, et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation. 2021;144(16):1295–307. https://doi.org/10.1161/CIRCULATIONAHA.121.056810.

PubMed  PubMed Central  Google Scholar 

Dragomir A, Touma N, Hu J, Perreault S, Aprikian AG. Androgen deprivation therapy and risk of cardiovascular disease in patients with prostate cancer based on existence of cardiovascular risk. J Natl Compr Canc Netw. 2023;21(2):163–71. https://doi.org/10.6004/jnccn.2022.7083.

CAS  PubMed  Google Scholar 

Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531–8. https://doi.org/10.1111/j.1464-410X.2008.08183.x.

CAS  PubMed  Google Scholar 

Noteboom EA, May AM, van der Wall E, de Wit NJ, Helsper CW. Patients’ preferred and perceived level of involvement in decision making for cancer treatment: a systematic review. Psychooncology. 2021;30(10):1663–79. https://doi.org/10.1002/pon.5750.

PubMed  PubMed Central  Google Scholar 

Menges D, Piatti MC, Cerny T, Puhan MA. Patient preference studies for advanced prostate cancer treatment along the medical product life cycle: systematic literature review. Patient Prefer Adherence. 2022;16:1539–57. https://doi.org/10.2147/PPA.S362802.

PubMed  PubMed Central  Google Scholar 

Kehl KL, Landrum MB, Arora NK, et al. Association of actual and preferred decision roles with patient-reported quality of care: shared decision making in cancer care. JAMA Oncol. 2015;1(1):50–8. https://doi.org/10.1001/jamaoncol.2014.112.

PubMed  PubMed Central  Google Scholar 

Connor MJ, Genie MG, Burns D, et al. A systematic review of patients’ values, preferences, and expectations for the treatment of metastatic prostate cancer. Eur Urol Open Sci. 2022;36:9–18. https://doi.org/10.1016/j.euros.2021.10.003.

PubMed  Google Scholar 

Kantar Health. Panels & Audiences. 2020. https://www.kantar.com/expertise/research-services/panels-and-audiences. Accessed 20 Nov 2023.

Hauber AB, González JM, Groothuis-Oudshoorn CG, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health. 2016;19(4):300–15. https://doi.org/10.1016/j.jval.2016.04.004.

PubMed  Google Scholar 

Reed Johnson F, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16(1):3–13. https://doi.org/10.1016/j.jval.2012.08.2223.

CAS  PubMed  Google Scholar 

Bridges JFP, Hauber AB, Marshall D, et al. Conjoint analysis applications in health–a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403–13. https://doi.org/10.1016/j.jval.2010.11.013.